Atrial Fibrillation News and Research

RSS

Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.

Estech receives FDA IDE approval to initiate enrollment in TCRF ablation trial for AF

Estech, a leader in minimally invasive and endoscopic cardiac ablation, announced today that the Food and Drug Administration (FDA) has given conditional Investigational Device Exemption (IDE) approval to initiate patient enrollment in the Estech-sponsored ATTAC-AF trial.

3 Apr 2012

Researchers identify genetic causes in nearly 1 in 5 patients with dilated cardiomyopathy

Researchers have identified genetic causes in nearly 1 in 5 patients who suffer a type of heart failure called dilated cardiomyopathy.

28 Mar 2012

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients.

27 Mar 2012

CRT-D appropriate for patients with left ventricular dysfunction

Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.

27 Mar 2012

CardioFocus introduces HeartLight Endoscopic Ablation System for AF in the Netherlands

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces its technology is now available in the Netherlands. Physicians at Isala Klinieken in Zwolle were the first in the country to incorporate visually guided ablation into their regular therapeutic practice and have successfully treated several patients.

26 Mar 2012

Heart Failure Congress 2012 to take place from May 19-22

Four days of scientific sessions will be devoted to the latest advances and controversies in heart failure at this year's Heart Failure Congress 2012. The latest results from drugs and devices trials will be announced at the meeting.

21 Mar 2012

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.

20 Mar 2012

CJC publishes updated atrial fibrillation guidelines

The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines.

20 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

Biomedical Systems launches wireless ambulatory ECG monitoring system for management of AF

Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia.

19 Mar 2012

Health Canada approves Boston Scientific's Blazer Open-Irrigated RFA Catheter

Boston Scientific Corporation today announced Health Canada approval of the Blazer Open-Irrigated Catheter, the Company's latest radiofrequency ablation (RFA) catheter designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia and other supraventricular tachycardias.

15 Mar 2012

New minimally invasive procedure can treat resistant hypertension

A radically different approach to treating high blood pressure - using a minimally invasive procedure- is being evaluated as part of a Pivotal Phase III 90-site national trial that includes The Carl H. and Edyth Lindner Center for Research and Education at The Christ Hospital.

8 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

Stereotaxis fourth quarter net loss increases to $5.5M

Stereotaxis, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2011.

6 Mar 2012

FDA takes more time to decide on the fate of BMS & Pfizer’s joint venture anticlotting drug Eliquis

The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That’s three months later than originally scheduled.

2 Mar 2012

FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA

Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

1 Mar 2012

AF strong predictor of cognitive and functional decline in older people at risk of heart disease

An irregular heartbeat - atrial fibrillation - is a strong predictor of cognitive decline and the loss of independence in daily activities in older people at risk of cardiovascular disease, according to a study in CMAJ.

28 Feb 2012

WATCHMAN device may prevent stroke in AF patients

In the United States alone, approximately 6 million people suffer from an irregular heartbeat called atrial fibrillation (AF), and since the incidence increases with age, it is predicted that 15.9 million Americans will be affected by 2050. The most devastating side effect of AF is stroke, but a new device from Boston Scientific may prevent them from occurring.

28 Feb 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

First use of HeartLight Endoscopic Ablation System to treat atrial fibrillation

For the first time in a new U.S. clinical trial, researchers at Mount Sinai School of Medicine have used the HeartLight Endoscopic Ablation System (EAS) to correct abnormal electrical signals inside the heart of a patient affected by atrial fibrillation (AFib), one of the nation's most common heart ailments.

22 Feb 2012